RaynesJGEaglingSMcAdamKP. Acute-phase protein synthesis in human hepatoma cells: Differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol1991; 83: 488–491.
2.
MurrayRKConnellGEPertJH. The role of haptoglobin in the clearance and distribution of extracorpuscular hemoglobin. Blood1961; 17: 45–53.
3.
KristiansenMGraversenJHJacobsenCet al.Identification of the haemoglobin scavenger receptor. Nature2001; 409: 198–201.
4.
BowmanBHKuroskyA. Haptoglobin. The evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet1982; 12: 189–261.
5.
LangloisMRDelangheJR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem1996; 42: 1589–1600.
6.
LevyAPHochbergIJablonskiKet al.Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol2002; 40: 1984–1990.
7.
RoguinAKochWKastratiAet al.Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care2003; 26: 2628–2631.
8.
SuleimanMAronsonDAslehRet al.Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes2005; 54: 2802–2806.
9.
ZafrirBAzencotMDobrecky-MeryIet al.Resting heart rate and measures of effort-related cardiac autonomic dysfunction predict cardiovascular events in asymptomatic type 2 diabetes. Eur J Prev Cardiol2016; 23: 1298–1306.
10.
VardiMBlumSLevyAP. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus – natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med2012; 23: 628–632.
11.
DalanRLiuh LingG. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus. Eur J Prev Cardiol. 2018; 25: 1502–1519.
12.
AdamsJNCoxAJFreedmanBIet al.Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the Diabetes Heart Study. Cardiovasc Diabetol2013; 12: 31–31.
13.
WuHWuHShiLet al.The association of haptoglobin gene variants and retinopathy in type 2 diabetic patients: A meta-analysis. J Diabetes Res2017; 2017: 2195059–2195059.
14.
LiGLiYChenXet al.Circulating tocopherols and risk of coronary artery disease: A systematic review and meta-analysis. Eur J Prev Cardiol2016; 23: 748–757.
15.
BurtonGWChengSCWebbAet al.Vitamin E in young and old human red blood cells. Biochim Biophys Acta1986; 860: 84–90.
16.
FahrenholtzSRDoleidenFHTrozzoloAMet al.On the quenching of singlet oxygen by alpha-tocopherol. Photochem Photobiol1974; 20: 505–509.
17.
LevyAPBlumS. Pharmacogenomics in prevention of diabetic cardiovascular disease: Utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Rev Cardiovasc Ther2007; 5: 1105–1111.
18.
VirtamoJRapolaJMRipattiSet al.Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med1998; 158: 668–675.
19.
De GaetanoG. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet2001; 357: 89–95.
20.
SaccoMFPellegriniMCRoncaglioniFet al.Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care2003; 26: 3264–3272.
21.
LeeIMCookNRGazianoJMet al.Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women’s Health Study: A randomized controlled trial. JAMA2005; 294: 56–65.
22.
SessoHDBuringJEChristenWGet al.Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians’ Health Study II randomized controlled trial. JAMA2008; 300: 2123–2133.
23.
StephensNGParsonsASchofieldPMet al.Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet1996; 347: 781–786.
24.
YusufSGDagenaisJPogueJet al.Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med2000; 342: 154–160.
25.
LonnEYusufSHoogwerfBet al.Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: Results of the HOPE study and MICRO-HOPE substudy. Diabetes Care2002; 25: 1919–1927.
26.
MannJFLonnEMYiQet al.Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE study. Kidney Int2004; 65: 1375–1380.
27.
LonnEBoschJYusufSet al.Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA2005; 293: 1338–1347.
28.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet2002; 360: 23–33.
29.
BoazMSmetanaSWeinsteinTet al.Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet2000; 356: 1213–1218.
30.
MilmanUBlumSShapiraCet al.Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: A prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol2008; 28: 341–347.
